We report on a patient with pathologically proven variant Creutzfeld-Jakob disease in whom chorea was a presenting feature of the disease, and was unaccompanied by the typical prodrome of psychiatric disturbance or sensory symptoms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/mds.10423 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Application of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington's disease.
Transl Neurodegener
January 2025
State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Key Laboratory of Non-Human Primate Research, Key Laboratory of CNS Regeneration (Ministry of Education), Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou, 510632, China.
Amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD) are diverse in clinical presentation and are caused by complex and multiple factors, including genetic mutations and environmental factors. Numerous therapeutic approaches have been developed based on the genetic causes and potential mechanisms of ALS and HD. Currently, available treatments for various neurodegenerative diseases can alleviate symptoms but do not provide a definitive cure.
View Article and Find Full Text PDFDiagnosing Huntington's disease on the medical ward.
BMJ Case Rep
January 2025
Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA
An African American man in his early 40s with progressive gait impairment and chronic cognitive impairment initially presented to the emergency department after statements of self-harm and was hospitalised. Examination revealed notable neurological abnormalities including impaired memory recall, oral dyskinesia/choreiform movements, dystonia of the right upper extremity with drift, hyper-reflexia and spastic gait. On further evaluation, including neurology and genetics consultation and workup, a clinical diagnosis of the neurodegenerative disorder Huntington's disease (HD) was made.
View Article and Find Full Text PDFEffect of Triheptanoin on Caudate Atrophy and Motor Scores in Patients With Early-Stage Huntington Disease: A Phase II Study.
Neurology
January 2025
APHP- Salpêtrière Hospital, DMU BioGem, CNRS, INSERM, Paris Brain Institute, Sorbonne University.
Background And Objectives: Brain energy deficiency occurs at the early stage of Huntington disease (HD). Triheptanoin, a drug that targets the Krebs cycle, can restore a normal brain energetic profile in patients with HD. In this study, we aimed at assessing its efficacy on clinical and neuroimaging structural measures in HD.
View Article and Find Full Text PDFAdvances in Stem Cell Therapy for Huntington's Disease: A Comprehensive Literature Review.
Cells
January 2025
Department of Neurosurgery, University of Florida, Gainesville, FL 32608, USA.
Huntington's disease (HD) is an inherited neurodegenerative disease characterized by uncontrolled movements, emotional disturbances, and progressive cognitive impairment. It is estimated to affect 4.3 to 10.
View Article and Find Full Text PDFCase Report: Utility of brain [F]FDG PET/CT in the diagnosis of Sydenham's chorea.
Front Nucl Med
December 2024
Radiopharmacist, CRCI2NA-Inserm UMR1307/CNRS UMR 6075, University of Angers, Angers, France.
Sydenham's chorea is an autoimmune reaction against cerebral basal ganglia associated with rheumatic fever, caused by group A beta-hemolytic streptococcus infection. Diagnosis of this condition is difficult because of significant delay between infection onset and symptoms presentation, resulting in few positive biological tests or imaging exams. We report the case of a nine-year-old boy exhibiting hemicorporal abnormal movements with tics for whom [F]FDG PET/CT exam allowed to make the diagnosis, associated with anti-DNase B elevation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!